Clinical Characteristics and Pathways of Care of Breast Cancer Patients Receiving Targeted Therapy in Hungary
Author(s)
Erdősi D1, Csanády B2, Zemplényi A2, Inotai A3, Agh T4
11) University of Pécs, Faculty of Pharmacy Center for Health Technology Assessment and Pharmacoeconomic Research, 2) Semmelweis University, Center for Health Technology Assessment, Budapest, BA, Hungary, 2University of Pécs, Pécs, Hungary, 3Semmelweis University, Budapest, PE, Hungary, 4University of Pécs, Esztergom, KE, Hungary
Presentation Documents
OBJECTIVES:
In Hungary, breast cancer is the most frequent cancer and was the second most common cause of tumor-related mortality among women in 2020. Growing collection of real-world health data enables a better understanding of cancer care pathways in diagnosis and the evaluation of treatment efficiency. We aimed to investigate the clinical characteristics and pathways of care of patients receiving targeted therapy for breast cancer in a real-world setting in Hungary.METHODS:
A retrospective analysis was conducted on the DataLake clinical database and on the itemized medication claims database of the University of Pécs. DataLake contains detailed data on in-, and out-patient services of all patients examined and/or treated at the University of Pécs. Patient characteristics, healthcare and medication data of patients diagnosed with breast cancer (ICD code: C50) in the time period between 2010 and 2020 and received targeted therapy were analyzed using the software R. Results were presented descriptively.RESULTS:
We identified 263 patients with breast cancer diagnosis who received targeted therapy. The majority of patients (n=262) were female; mean age at therapy initiation was 59.51 (SD 12.45) years. Two hundred and twelve patients had stage II-IV breast cancer, 243 patients were HER2 positive and the majority of patients had surgery (n=189). During follow-up until 2020, 70 patients died. Patients were treated with different targeted therapies, i.e., bevacizumab (n=49), trastuzumab (n=216), trastuzumab emtansine (n=7), pertuzumab (n=16) and lapatinib (n=13). The mean time from initial diagnosis to the start of targeted therapy was 259.84 (SD 437.29) days. Mean length of therapy was 570.16 (SD 1083.68) days per patient. Over the study period, 31 patients switched from one medication to another at least once.CONCLUSIONS:
The availability and analysis of real-world data contribute to optimizing the management, and consequently, health outcomes of future breast cancer patients.Conference/Value in Health Info
2022-11, ISPOR Europe 2022, Vienna, Austria
Value in Health, Volume 25, Issue 12S (December 2022)
Code
RWD154
Topic
Real World Data & Information Systems, Study Approaches
Topic Subcategory
Electronic Medical & Health Records, Health & Insurance Records Systems
Disease
STA: Drugs